Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia

Blood

Volumn 109, Issue 6, 2007, Pages 2470-2476

  Deng, Rong ^a   Balthasar, Joseph P ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE ANTIBODY; IMMUNOGLOBULIN; LIPOSOME; METHOTREXATE ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MWREG30; TER 119; THROMBOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COATING; DRUG MECHANISM; ERYTHROCYTE COUNT; FEMALE; HEMOLYSIS; IMMUNE THROMBOCYTOPENIA; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 33947258033     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-04-018093     Document Type: Article

References (30)

1. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol. 2000;37:239-248.
2. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments]. Blood. 1996;88:3-40.
3. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120:574-596.
4. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995-1008.
5. Imbach P, d'Apuzzo V, Hirt A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228-1231.
6. Salama A, Mueller Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet. 1983;2:193-195.
7. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997;89:2689-2700.
8. Ware RE, Zimmerman SA. Anti-D: mechanisms of action. Semin Hematol. 1998;35:14-22.
9. Hong F, Ruiz R, Price H, Griffiths A, Malinoski F, Woloski M. Safety profile of WinRho anti-D. Semin Hematol. 1998;35:9-13.
10. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood. 2005;106:1532-1537.
11. Deng R, Balthasar JP. Investigation of antibody-coated liposomes as a new treatment for immune thrombocytopenia. Int J Pharm. 2005;304:51-62.
12. Lobo ED, Soda DM, Balthasar JP. Application of pharmacokinetic- pharmacodynamic modeling to predict the kinetic and dynamic effects of antimethotrexate antibodies in mice. J Pharm Sci. 2003;92:1665-1676.
13. Berger N, Sachse A, Bender J, Schubert R, Brandl M. Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. Int J Pharm. 2001;223:55-68.
14. Maruyama K, Takizawa T, Yuda T, Kennel SJ, Huang L, Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta. 1995;1234:74-80.
15. Rouser G, Fkeischer S, Yamamoto A. Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 1970;5:494-496.
16. Heath TD, Macher BA, Papahadjopoulos D. Covalent attachment of immunoglobulins to liposomes via glycosphingolipids. Biochim Biophys Acta. 1981;640:66-81.
17. Hansen RJ, Balthasar JP. An ELISA for quantifi-cation of murine IgG in rat plasma: application to the pharmacokinetic characterization of AP-3, a murine anti-glycoprotein IIIa monoclonal antibody, in the rat. J Pharm Biomed Anal. 1999;21:1011-1016.
18. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood. 2002;100:2087-2093.
19. Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost. 2002;88:898-899.
20. Hansen RJ, Balthasar JP. Pharmacokinetics, pharmacodynamics, and platelet binding of 7E3, a murine anti-glycoprotein IIb/IIIa monoclonal antibody in the rat. J Pharmacol Exp Ther. 2001;298:165-171.
21. Song S, Crow AR, Freedman J, Lazarus AH. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood. 2003;101:3708-3713.
22. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484-486.
23. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood. 2001;98:1095-1099.
24. Hansen RJ, Balthasar JP. PK/PD modeling of the effects of intravenous immunoglobulin on the disposition of anti-platelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci. 2003;92:1206-1215.
25. Hansen RJ, Balthasar JP. Mechanisms of IVIG action in immune thrombocytopenic purpura. Clin Lab. 2004;50:133-140.
26. Blanchette VS, Kirby MA, Turner C. Role of intravenous immunoglobulin G in autoimmune hematologic disorders. Semin Hematol. 1992;29:72-82.
27. Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci. 2003;28:249-255.
28. Coopamah MD, Freedman J, Semple JW. Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist. Blood. 2003;102:2862-2867.
29. Cooper N, Heddle NM, Haas M, et al. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol. 2004;124:511-518.
30. Siragam V, Brinc D, Crow AR, Song S, Freedman J, Lazarus AH. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest. 2005;115:155-160.